Akari Therapeutics (AKTX) Non Operating Income (2014 - 2026)
Akari Therapeutics' (AKTX) quarterly Non Operating Income came in at $444000.0 in Q1 2026, up 346.67% year-on-year from $99403.0 in Q1 2025, and up 122.36% quarter-over-quarter from -$2.0 million in Q4 2025.
Akari Therapeutics (AKTX) Non Operating Income (2014 - 2026) Analysis & Trends
Akari Therapeutics has disclosed Non Operating Income across 9 years of filings, most recently posting $444000.0 for Q1 2026.
- Non Operating Income for Q1 2026 came in at $444000.0, up 346.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$402000.0 (up 98.58% YoY), and the FY2025 annual result was -$1.0 million, down 155.4% from the prior year.
- Non Operating Income came in at $444000.0 for Q1 2026 at Akari Therapeutics, up from -$2.0 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.2 million in Q2 2025 to a low of -$28.0 million in Q4 2024.
- The 4-year median for Non Operating Income is -$13000.0 (2023), against an average of -$2.1 million.
- Peak annual rise in Non Operating Income reached 3945.45% in 2024, while the deepest fall reached 3041.91% in 2024.
- Akari Therapeutics' Non Operating Income stood at $952000.0 in 2023, then plunged by 3041.91% to -$28.0 million in 2024, then jumped by 92.91% to -$2.0 million in 2025, then surged by 122.36% to $444000.0 in 2026.
- The last three Non Operating Income figures came in at $444000.0 (Q1 2026), -$2.0 million (Q4 2025), and -$84000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 201.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 444,000.00 |
| Dec 31, 2025 | -1.99 Mn |
| Sep 30, 2025 | -84,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | -180,000.00 |
| Dec 31, 2024 | -28.01 Mn |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | -109,000.00 |
| Mar 31, 2024 | 423,000.00 |
| Dec 31, 2023 | 952,000.00 |
| Sep 30, 2023 | -22,000.00 |
| Jun 30, 2023 | -13,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Dec 31, 2020 | 85,659.00 |
| Sep 30, 2020 | 1.16 Mn |
| Jun 30, 2020 | -1.53 Mn |
| Mar 31, 2020 | 1.18 Mn |
| Dec 31, 2019 | -3,710.00 |
| Sep 30, 2019 | 235,426.00 |
| Jun 30, 2019 | 83,674.00 |